BridgeBio Pharma, Inc.
BBIO
$66.92
$0.971.47%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Revenue | 66.78% | 2,521.18% | 4,318.01% | 4,999.86% | -44.76% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 66.78% | 2,521.18% | 4,318.01% | 4,999.86% | -44.76% |
| Cost of Revenue | 276.62% | 289.01% | 997.49% | 510.87% | 341.30% |
| Gross Profit | 61.92% | 3,746.00% | 5,248.50% | 6,709.68% | -45.85% |
| SG&A Expenses | 54.09% | 66.79% | 99.98% | 116.98% | 61.63% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 36.31% | 24.38% | 35.39% | 39.60% | 6.30% |
| Operating Income | -2.08% | 41.97% | 27.13% | 22.69% | -2,873.23% |
| Income Before Tax | 1.80% | 26.85% | -13.53% | -140.47% | -369.05% |
| Income Tax Expenses | -- | -110.41% | -- | -- | -- |
| Earnings from Continuing Operations | 1.80% | 27.21% | -12.59% | -143.25% | -369.05% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | 14.91% | -24.24% | -0.90% | -11.16% | 131.57% |
| Net Income | 2.02% | 27.24% | -12.78% | -147.64% | -375.41% |
| EBIT | -2.08% | 41.97% | 27.13% | 22.69% | -2,873.23% |
| EBITDA | -2.20% | 42.27% | 27.28% | 22.75% | -2,020.17% |
| EPS Basic | 4.35% | 28.78% | -10.81% | -143.82% | -346.73% |
| Normalized Basic EPS | -9.88% | 31.36% | 17.78% | 10.45% | -959.38% |
| EPS Diluted | 4.35% | 28.78% | -10.81% | -143.82% | -346.73% |
| Normalized Diluted EPS | -9.88% | 31.36% | 17.78% | 10.45% | -959.38% |
| Average Basic Shares Outstanding | 2.44% | 2.17% | 1.77% | 1.56% | 6.40% |
| Average Diluted Shares Outstanding | 2.44% | 2.17% | 1.77% | 1.56% | 6.40% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |